Trial Profile
The Effect of Eprosartan in Patients With Essential Hypertension on Renal Tubular Function and Vasoactive Hormones During Baseline Conditions and After Activation of the Sympathetic Nervous System.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Eprosartan (Primary)
- Indications Essential hypertension
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 05 Oct 2010 Status changed from active, no longer recruiting to completed.
- 26 Sep 2010 Primary endpoint 'Noradrenaline levels' has not been met.
- 26 Sep 2010 Primary endpoint 'Sodium levels' has been met.